Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market

Stock Information for Fortress Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Fortress Biotech Inc.

Robbins LLP Reminds Stockholders of CKPT to Contact the Law Firm for Information About the Checkpoint Therapeutics, Inc. Class Action Lawsuit
CKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud Lawsuit
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm
CKPT SHAREHOLDER ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CKPT
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
ROSEN, A TOP RANKED LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CKPT
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.